The Founder Mutation MSH2*1906G→C Is an Important Cause of Hereditary Nonpolyposis Colorectal Cancer in the Ashkenazi Jewish Population
William D. Foulkes(McGill University Health Centre), Natasha A. Ellis, Nancy Hamel(McGill University), Debora B. Farber(Doheny Eye Institute), Jeff Boyd(Northwell Health), Celia M.T. Greenwood(University of Toronto), Heather Hampel(City of Hope), Arnold J. Markowitz(Memorial Sloan Kettering Cancer Center), Johannes Gebert(Heidelberg University), Isabelle Thiffault(Children's Mercy Hospital), Marshall S. Horwitz(University of Washington), Jeffrey N. Weitzel(Cancer Genetics (United States)), Eitan Friedman(University of Pennsylvania), Khédoudja Nafa(Memorial Sloan Kettering Cancer Center), Elizabeth MacNamara(McGill University Health Centre), Joseph D. Bonner(Michigan Medicine), Clara Gaff(The University of Melbourne), Victoria Marcus(Montreal General Hospital), Mary‐Claire King(University of Washington), Brigitte Bressac–de Paillerets(Institut Gustave Roussy), Albert de la Chapelle(Université Claude Bernard Lyon 1), Finlay Macrae(The Royal Melbourne Hospital), Stephen B. Gruber(City Of Hope National Medical Center), Jinru Shia(Memorial Sloan Kettering Cancer Center), Peter K. Gregersen(Northwell Health), Gad Rennert(Technion – Israel Institute of Technology), Tom Walsh(University of Washington), George Chong(Jewish General Hospital), Lynn Tomsho(University of Michigan), C. Lee(Memorial Sloan Kettering Cancer Center), Arié Figer(Ontario Institute for Cancer Research), Kenneth Offit(Memorial Sloan Kettering Cancer Center)
Cited by 134
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k